CFTR and cystic fibrosis: Combination therapies of corrector(s) and a potentiator (Orkambi®, Symdeko/Symkevi®, Trikafta/Kaftrio®) have been approved for CF individuals with F508del, the most common CFTR mutation, as well as several specific residual function mutations.